VCP (Valosin-containing protein), also known as p97, is a highly conserved AAA+ ATPase that plays central roles in protein quality control, autophagy, DNA repair, and cellular stress responses. VCP is essential for maintaining proteostasis in all eukaryotic cells, with particular importance in neurons. Mutations in VCP cause Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), and inclusion body myopathy, establishing VCP as a critical nexus in neurodegeneration. [1]
| VCP/p97 | |
|---|---|
| Protein Name | Valosin-containing protein (p97) |
| Gene | VCP |
| UniProt ID | P55072 |
| PDB IDs | 1R3R, 3EAA, 5C0B, 5MLV |
| Molecular Weight | 97 kDa |
| Subcellular Localization | Cytoplasm, nucleus, ER, mitochondria |
| Protein Family | AAA+ ATPase family |
| Associated Diseases | ALS, FTD, Inclusion Body Myopathy, PDB |
VCP/p97 is a 806-amino acid AAA+ ATPase that functions as a molecular chaperone. It is one of the most abundant proteins in cells and is essential for viability. VCP forms hexameric rings that use ATP hydrolysis to extract ubiquitinated substrates from membranes or protein complexes. This segregase activity underlies its functions in multiple cellular pathways:
Mutations in VCP cause a spectrum of diseases including ALS, FTD, and inclusion body myopathy with early-onset Paget disease of bone (PDB).
VCP contains several distinct structural domains:
N-terminal domain (NTD, residues 1-200): Binds cofactors and substrates. Contains two subdomains that adopt a double ψ β-barrel fold.
D1 ATPase domain (residues 200-480): First AAA+ module with Walker A (P-loop) and Walker B motifs. Undergoes conformational changes during ATP hydrolysis.
D2 ATPase domain (residues 480-760): Second AAA+ module with the major ATPase activity. Essential for hexamer formation.
C-terminal tail (residues 760-806): Contains final residues and interaction sites for substrates and cofactors.
VCP functions as a hexamer:
VCP interacts with numerous cofactors that determine its substrate specificity:
| Cofactor | Function |
|---|---|
| UFD1-NPL4 | Ubiquitin recognition in ERAD and autophagy |
| p47 | Membrane fusion, nuclear envelope reformation |
| UBXD1 | ER stress response |
| UBXD8 | ERAD substrate recruitment |
| PLAA | Autophagosome maturation |
VCP is central to ERAD:
VCP facilitates multiple autophagy pathways:
VCP participates in DNA double-strand break repair:
VCP maintains mitochondrial health:
In neurons, VCP is essential for:
VCP is ubiquitously expressed with high levels in:
In neurons, VCP localizes to:
Over 50 VCP mutations cause ALS/FTD:
| Mutation | Type | Effect |
|---|---|---|
| R155H | Missense | Impaired cofactor binding |
| R191Q | Missense | Reduced ATPase activity |
| A232T | Missense | Disrupted substrate processing |
| D592N | Missense | Altered ubiquitination |
Mechanism:
VCP interacts with key neurodegeneration-related proteins:
| Approach | Status | Description |
|---|---|---|
| VCP modulators | Research | Small molecules enhancing VCP function |
| Autophagy enhancers | Research | Bypassing VCP dysfunction |
| Proteostasis promoters | Research | Supporting protein quality control |
| Gene therapy | Preclinical | Restoring VCP expression |
The study of Vcp Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Johnson JO, Mandrioli J, Benatar M, et al. Exome sequencing reveals VCP mutations as a cause of familial ALS. Nature. 2010;466:1069-1073. 2010. ↩︎